9M 2023 Financial Overview
9M 2023: APPENDIX
9M 2023: Product distribution of revenue & YoY growth
DKKm
FY 2021
FY 2022
9M 2023
9M 2022
Growth
Growth
(CER)
% of total 9M
2023
Rexulti
2,849
3,890
3,309
2,817
17%
19%
22%
Brintellix/Trintellix
3,526
4,277
3,207
3,177
1%
4%
22%
Abilify Maintena¹)
2,420
2,964
2,374
2,164
10%
11%
16%
Vyepti
492
1,004
1,201
672
79%
81%
8%
Strategic brands
9,287
12,135
10,091
8,830
14%
16%
68%
Cipralex/Lexapro
2,346
2,360
1,701
1,874
(9%)
(5%)
12%
Sabril
657
636
318
482
(34%)
(34%)
2%
Other pharmaceuticals²)
3,609
3,426
2,587
2,576
0%
3%
17%
Other revenue
347
277
193
205
(6%)
(7%)
1%
Revenue before hedging
16,246
18,834
14,890
13,967
7%
9%
100%
Effects from hedging
Total revenue
35
53
16,299
(588)
18,246
44
(401)
0%
14,934
13,566
10%
9%
100%
1) Includes Abilify Asim tufii figures. 2) As of January 1, 2023, Onfi is being reported together with Other pharmaceuticals, comparative figures for 2022 have been adjusted accordingly
LundbeckView entire presentation